Company Description: Immunophotonics, Inc. is developing an innovative therapy to prevent cancer from coming back after local tumor destruction (ablation) therapy. Advancements in cancer treatment, such as precision medicines and immune checkpoint inhibitors, have significantly improved cancer patient survival. However, tumor recurrence remains a major challenge for those undergoing curative therapies. The uncertainty of whether cancer will return after treatment weighs heavily on patients and their families. As pioneers of Interventional Immuno-Oncology® Immunophotonics, we are at the forefront of cancer care. The company's goal is to turn local tumor destruction into a systemic immune response that provides long-lasting protection against cancer recurrence. Our proprietary lead molecule, IP-001, is a novel cancer immunotherapy developed by Immunophotonics. It can stimulate the patient's immune system to create a robust defense against cancer following standard tumor ablation therapies.

Goal for Presentation: • Discuss Immunophotonics’ potential to transform cancer care with our lead asset IP-001. We will be providing updates of our encouraging clinical data, the company’s robust IP position, and global market opportunity. • Engage with potential investors. • Meet with pharma and biotechnology companies to explore potential for collaborative opportunities to expand clinical capabilities and indications. • Initiate discussions on nonclinical collaborations for non-oncology uses of IP-001.

Additional Comments:

Who referred you to this application?: